SCYNEXIS, Inc. (SCYX)

Several events have impacted SCYNEXIS, Inc.'s stock price in the past six months. SCYNEXIS reported a net revenue of $2.11 million for Q2 2025, missing earnings estimates but showing short-term market resilience. The company reported Q3 2025 earnings per share (EPS) of -$0.17, beating the consensus estimate. SCYNEXIS completed the transfer of the BREXAFEMME New Drug Application to GSK. SCYNEXIS received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. SCYNEXIS announced that SCY-247 received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations. The company announced presentations highlighting the potent antifungal activity of SCY-247 at the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI). SCYNEXIS anticipates the restart of the Phase 3 MARIO study for invasive candidiasis in Q2 2025, pending the FDA lifting a clinical hold. Over the past year, SCYX underperformed the US Pharmaceuticals industry and the US Market.

Information regarding specific demand seasonality for SCYNEXIS, Inc.'s products and services is not readily available. Demand is likely driven by disease incidence rather than seasonal consumer trends.

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies for difficult-to-treat infections, operating in the Healthcare sector as a Drug Manufacturer. The company has discovered and developed over 30 innovative medicines across various therapeutic areas. Its major products include BREXAFEMME (ibrexafungerp), approved for VVC and recurrent VVC, with the New Drug Application transferred to GSK in November 2025. Ibrexafungerp is the company's lead product candidate for various fungal infections, and SCY-247 is a second-generation antifungal in development for severe invasive fungal infections, with a Phase 1 trial initiated in December 2024 and FDA designations received.

SCYNEXIS, Inc. primarily develops medicines in the United States. The company has expanded its clinical footprint, conducting trials in both North America and Europe.

SCYNEXIS's reputation has been influenced by its ongoing drug development and regulatory progress. SCY-247 receiving Qualified Infectious Disease Product (QIDP) and Fast Track Designations highlights the potential importance of this antifungal. Presentations at events like the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) demonstrates scientific engagement. SCYNEXIS scored higher than 35% of companies evaluated by MarketBeat and ranked 722nd out of 872 stocks in the medical sector, indicating a moderate standing within its industry.

SCYNEXIS, Inc. has 48 institutional owners and shareholders holding a total of 12,036,395 shares. Major institutional owners include Avidity Partners Management LP, FKASX - Federated Kaufmann Small Cap Fund Class A Shares, Kingdon Capital Management, L.l.c., Vanguard Group Inc, Federated Hermes, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VEXMX - Vanguard Extended Market Index Fund Investor Shares, KAUAX - Federated Kaufmann Fund Class A Shares, Geode Capital Management, Llc and Acadian Asset Management Llc.